Dendritic Biomaterials for Oral Delivery of Chemotherapeutics
用于口服化疗药物的树突状生物材料
基本信息
- 批准号:7627049
- 负责人:
- 金额:$ 31.34万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-08-22 至 2011-04-30
- 项目状态:已结题
- 来源:
- 关键词:Biocompatible MaterialsBiological AvailabilityBiopolymersBlood CirculationCamptothecin AnalogueCharacteristicsChargeChemistryColorectal CancerDataDendrimersDrug Delivery SystemsDrug TransportDrug toxicityDrug usageEnvironmentEnzymesEpithelialEpithelial CellsEpitheliumEquilibriumExhibitsHydrolysisIn SituIn VitroIntestinesLabelMetastatic Neoplasm to the LiverModelingMucous MembraneMusNatureOralPathway interactionsPermeabilityPharmaceutical PreparationsPolymersProcessResearchRouteSN-38SiteSystemTestingTherapeuticToxic effectWaterabsorptionbasecytotoxicitydesigngastrointestinalimprovedin vivointestinal epitheliummonolayernovelprototypesizesmall moleculetargeted delivery
项目摘要
DESCRIPTION (provided by applicant): Targeted delivery of drugs using water-soluble polymeric carriers improves efficacy and reduces toxicity. However, the large size of most biopolymers necessitates administration via the parenteral route. As oral absorption remains the preferred route of administration, many pharmacologically active drugs as well as polymers have poor systemic availability when administered orally. Our preliminary data indicate that poly(amidoamine) (PAMAM) dendrimers efficiently translocate across epithelial cell monolayers and can effectively increase the transfer of small molecules. Thus, this polymeric carrier may be used to improve the oral absorption of therapeutic molecules into the systemic circulation and direct them to the target sites via the creation of a conjugate delivery system. In the current proposal we aim to evaluate the influence of structural features of PAMAM dendrimers on their transepithelial transport and capitalize on both their permeation enhancing effects to increase the oral bioavailability and their macromolecular nature to facilitate targeting of a model drug. The long-term objective of this proposal is to develop polymeric systems based on PAMAM dendrimers for targeted oral drug delivery. The central hypothesis to our proposed research is that the permeation and targeting potential of poorly absorbable drugs is enhanced by conjugation to PAMAM dendrimers. To test our hypothesis, we will study the following Specific Aims: 1) To evaluate the influence of charge and drug loading on intestinal transport and cytotoxicity of PAMAM dendrimers. 2) To evaluate the in vitro stability and in situ bioavailability of dendrimer-drug conjugates. 3) To evaluate the in vivo bioavailability, antitumor efficacy and toxicity of the conjugates in a murine model of liver metastasis of colorectal cancer. 4) To delineate the intestinal transport mechanism(s) of PAMAM dendrimers. By evaluating the influence of structural features on permeability and stability we expect to find prototype PAMAM dendrimers that can increase oral availability of SN38, exhibit minimal toxicity, and target the drug effectively to liver metastases. Delineation of the mechanism(s) of transport will aid in the rationale design of novel polymeric carriers for oral delivery. In the long term this may allow for the delivery of a variety of therapeutic molecules in a more controlled and targeted manner across the Gl tract using tailor-made PAMAM dendrimers as polymeric carriers.
描述(由申请人提供):使用水溶性聚合物载体靶向递送药物可提高疗效并降低毒性。然而,大多数生物聚合物尺寸较大,需要通过肠胃外途径给药。由于口服吸收仍然是优选的给药途径,因此许多药理活性药物以及聚合物在口服给药时的全身利用度较差。我们的初步数据表明,聚(酰胺基胺)(PAMAM)树枝状聚合物可以有效地跨上皮细胞单层易位,并且可以有效地增加小分子的转移。因此,这种聚合物载体可用于改善治疗分子进入体循环的口服吸收,并通过创建缀合物递送系统将它们引导至靶位点。在当前的提案中,我们的目标是评估 PAMAM 树枝状聚合物的结构特征对其跨上皮转运的影响,并利用其渗透增强作用来提高口服生物利用度及其大分子性质,以促进模型药物的靶向。该提案的长期目标是开发基于 PAMAM 树枝状聚合物的聚合物系统,用于靶向口服药物递送。我们提出的研究的中心假设是,吸收性差的药物的渗透和靶向潜力通过与 PAMAM 树枝状聚合物的缀合而增强。为了检验我们的假设,我们将研究以下具体目标:1)评估电荷和药物负载对 PAMAM 树枝状聚合物肠道转运和细胞毒性的影响。 2) 评估树枝状聚合物-药物缀合物的体外稳定性和原位生物利用度。 3)在结直肠癌肝转移小鼠模型中评价缀合物的体内生物利用度、抗肿瘤功效和毒性。 4) 描述 PAMAM 树枝状聚合物的肠道转运机制。通过评估结构特征对渗透性和稳定性的影响,我们期望找到原型 PAMAM 树枝状聚合物,它可以增加 SN38 的口服利用度,表现出最小的毒性,并有效地将药物靶向肝转移。运输机制的描述将有助于新型口服聚合物载体的基本原理设计。从长远来看,这可以允许使用定制的PAMAM树枝状聚合物作为聚合物载体以更受控和更有针对性的方式跨胃肠道递送多种治疗分子。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Hamid Ghandehari其他文献
Hamid Ghandehari的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Hamid Ghandehari', 18)}}的其他基金
Localized delivery of glycosaminoclycan ethers for the treatment of radiation-induced proctitis
局部递送糖胺聚糖醚治疗放射性直肠炎
- 批准号:
10296670 - 财政年份:2018
- 资助金额:
$ 31.34万 - 项目类别:
Localized delivery of glycosaminoclycan ethers for the treatment of radiation-induced proctitis
局部递送糖胺聚糖醚治疗放射性直肠炎
- 批准号:
10530585 - 财政年份:2018
- 资助金额:
$ 31.34万 - 项目类别:
Localized delivery of glycosaminoclycan ethers for the treatment of radiation-induced proctitis
局部递送糖胺聚糖醚治疗放射性直肠炎
- 批准号:
10058818 - 财政年份:2018
- 资助金额:
$ 31.34万 - 项目类别:
In-situ Gelling Protein Polymer Intravascular Embolic Agent for Hepatic Carcinoma
原位胶凝蛋白聚合物血管内栓塞剂治疗肝癌
- 批准号:
8314876 - 财政年份:2012
- 资助金额:
$ 31.34万 - 项目类别:
Targeted Polymeric Combination Delivery for Treatment of Ovarian Cancer
用于治疗卵巢癌的靶向聚合物组合递送
- 批准号:
7999063 - 财政年份:2010
- 资助金额:
$ 31.34万 - 项目类别:
Biological fate and biocompatibility of dendritic and silica-based nanoconstructs
树枝状和二氧化硅基纳米结构的生物命运和生物相容性
- 批准号:
7615449 - 财政年份:2007
- 资助金额:
$ 31.34万 - 项目类别:
Biological fate and biocompatibility of dendritic and silica-based nanoconstructs
树枝状和二氧化硅基纳米结构的生物命运和生物相容性
- 批准号:
7916398 - 财政年份:2007
- 资助金额:
$ 31.34万 - 项目类别:
Dendritic Biomaterials for Oral Delivery of Chemotherapeutics
用于口服化疗药物的树突状生物材料
- 批准号:
7633399 - 财政年份:2007
- 资助金额:
$ 31.34万 - 项目类别:
Biological fate and biocompatibility of dendritic and silica-based nanoconstructs
树枝状和二氧化硅基纳米结构的生物命运和生物相容性
- 批准号:
7341354 - 财政年份:2007
- 资助金额:
$ 31.34万 - 项目类别:
Dendritic Biomaterials for Oral Delivery of Chemotherapeutics
用于口服化疗药物的树突状生物材料
- 批准号:
7848308 - 财政年份:2007
- 资助金额:
$ 31.34万 - 项目类别:
相似国自然基金
α-乳白蛋白姜黄素纳米复合物通过PepT1-溶酶体提高生物利用度对镉致动脉粥样硬化的干预作用机制研究
- 批准号:82373600
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
基于果蔬胞外囊泡传递体系负载疏水多酚及其生物利用度增效机制
- 批准号:32302070
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
植物三萜羽扇豆醇高生物利用度纳米超分子自组装结构的详细解析及提升机制研究
- 批准号:32300336
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
脂肪酸甘油酯/磷脂对乳液界面演变及营养素生物利用度的调控机制
- 批准号:32372325
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
基于神经血管单元研究参附注射液抑制eNOS解耦增加NO生物利用度抗血管性痴呆的机制
- 批准号:82360880
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
相似海外基金
Protease Operated Depot for Delivery of GLP-1
用于递送 GLP-1 的蛋白酶操作库
- 批准号:
8317236 - 财政年份:2012
- 资助金额:
$ 31.34万 - 项目类别:
Protease Operated Depot for Delivery of GLP-1
用于递送 GLP-1 的蛋白酶操作库
- 批准号:
8447002 - 财政年份:2012
- 资助金额:
$ 31.34万 - 项目类别:
Protease Operated Depot for Delivery of GLP-1
用于递送 GLP-1 的蛋白酶操作库
- 批准号:
8821610 - 财政年份:2012
- 资助金额:
$ 31.34万 - 项目类别:
Dendritic Biomaterials for Oral Delivery of Chemotherapeutics
用于口服化疗药物的树突状生物材料
- 批准号:
7633399 - 财政年份:2007
- 资助金额:
$ 31.34万 - 项目类别:
Dendritic Biomaterials for Oral Delivery of Chemotherapeutics
用于口服化疗药物的树突状生物材料
- 批准号:
7848308 - 财政年份:2007
- 资助金额:
$ 31.34万 - 项目类别: